Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Cytokinetics, Incorporated - Common Stock (NQ:CYTK)

49.44 -1.69 (-3.31%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cytokinetics, Incorporated - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
Expert Ratings for Cytokinetics
 
Via Benzinga
Potential Takeover In Works for Cardiovascular Treatment Focused Cytokinetics
Cytokinetics Inc (NASDAQ: CYTK), a late-stage biotech company focused on cardiovascular treatments, is reportedly exploring potential takeover options as it has garnered interest from at least one... 
Via Benzinga
HC Wainwright & Co. Maintains Buy Rating for Cytokinetics: Here's What You Need To Know
 
Via Benzinga
Union Pacific To Rally Around 12%? Here Are 10 Top Analyst Forecasts For Friday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page 
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
Expert Ratings for Cytokinetics
 
Via Benzinga
Where Cytokinetics Stands With Analysts
 
Via Benzinga
Where Cytokinetics Stands With Analysts
 
Via Benzinga
Why CalAmp Shares Are Trading Lower By Around 32%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Gainers 
Via Benzinga
NuScale Power, Stagwell And Other Big Stocks Moving Higher On Friday
U.S. stocks traded higher, with the Nasdaq Composite gaining around 50 points on Friday. Here are some big stocks recording gains in Friday's session. 
Via Benzinga
Topics Stocks
11 Analysts Have This to Say About Cytokinetics
 
Via Benzinga
What 20 Analyst Ratings Have To Say About Cytokinetics
 
Via Benzinga
18 Analysts Have This to Say About Cytokinetics
 
Via Benzinga
Cytokinetics: Q1 Earnings Insights
 
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
The 3 Best Mid-Cap Stocks to Buy Now: September 2023
With the best mid-cap stocks to buy, investors get the best of both worlds: an established business but with ample room to grow. 
Via InvestorPlace
10 Health Care Stocks With Whale Alerts In Today's Session
 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 15, 2023
 
Via Benzinga
Analyst Ratings for Cytokinetics
 
Via Benzinga
Analyst Expectations for Cytokinetics's Future
 
Via Benzinga
Analyst Ratings for Cytokinetics
 
Via Benzinga
Atlassian, Universal Display, Booking, Dropbox And Other Big Stocks Moving Higher On Friday
U.S. stocks traded higher, with the Dow Jones gaining around 150 points on Friday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
5 Biotech Stocks That Could Soar Thanks To These Disruptive Healthcare Technologies
 
Via Benzinga
Cytokinetics Plans To Discontinue Late-Stage ALS Trial Due To Futility
Cytokinetics Incorporated (NASDAQ: CYTK) announced that the Data Monitoring Committee (DMC) for COURAGE-ALS recently convened to conduct the second planned interim analysis of this Phase 3 clinical... 
Via Benzinga
FDA Rejects Cytokinetics' Heart Failure Treatment Candidate
 
Via Benzinga
Earnings Scheduled For March 1, 2023
Companies Reporting Before The Bell • Globalstar (AMEX:GSAT) is expected to report quarterly loss at $0.01 per share on revenue of $38.75 million. 
Via Benzinga
Cytokinetics's Earnings: A Preview
 
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
  Wednesday saw 59 companies set new 52-week lows. 
Via Benzinga
Cytokinetics Posts Aficamten Data In Patients With Thickened Heart Muscle
 
Via Benzinga
Stocks That Hit 52-Week Lows On Monday
  On Monday morning, 70 companies achieved new lows for the year. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.